https://qibawiki.rsna.org/api.php?action=feedcontributions&user=Abuckler&feedformat=atomQIBA Wiki - User contributions [en]2024-03-29T15:02:17ZUser contributionsMediaWiki 1.35.5https://qibawiki.rsna.org/index.php?title=File:Profile_V0_3_LungDensity_070111.doc&diff=3269File:Profile V0 3 LungDensity 070111.doc2011-07-01T14:25:05Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:Profile_V0_2_LungDensity_052411.doc&diff=3268File:Profile V0 2 LungDensity 052411.doc2011-07-01T14:24:44Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Lung_Density_Biomarker_Ctte&diff=3267Lung Density Biomarker Ctte2011-07-01T14:23:44Z<p>Abuckler: </p>
<hr />
<div>__NOTOC__<br />
This Wiki is for collaborative creation of QIBA's Chronic Obstructive Pulmonary Disease (COPD) and Asthma Committee materials and ongoing activities.<br />
<br />
<br />
'''Mission''': Reduce and characterize bias and variance across manufacturers, versions, and sites in support of quantitative CT lung densitometry and morphology. <br />
<br />
'''Initial Objectives''':<br />
:* Characterize the precision and accuracy of phenotyping and progression measurements in emphysema and asthma. <br />
:: This is an essential effort to classify phenotype and assess longitudinal changes as medically meaningful surrogates for health status. <br />
:* Compare the sensitivity of CT measurements to spirometry and other accepted measures. <br />
:: This will be necessary in order to determine if Progressive Disease can be detected significantly sooner with quantitative imaging techniques than with currently accepted methods.<br />
<br />
<br />
==Profiling Activities==<br />
<br />
* [[Media:Profile_V0_3_LungDensity_070111.doc|Lung Density QIBA Profile 7/1/11 v0.3]]<br />
* [[Media:Profile_V0_2_LungDensity_052411.doc|Lung Density QIBA Profile 5/24/11 v0.2]]<br />
* [[Media:Profile_V0_2_Asthma_COPD_03192011.doc|COPD QIBA Profile 3/19/11 v0.2]]<br />
* [[Media:Protocol_V0_2_Asthma_COPD_03192011.doc|COPD UPICT Protocol v0.2]]<br />
<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
<br />
* [[Claim Language/Detail]]<br />
<br />
==Protocol Development Activities==<br />
<br />
*[http://upictwiki.ctsa-imaging.org/index.php?title=UPICT_Template UPICT Template]<br />
<br />
==Groundwork Activities==<br />
Validate key concepts and answer key questions needed to write the Profiles and demonstrate their effectiveness.<br />
<br />
* Phantom project<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[COPD Group Call Summaries]]<br />
<br />
<br />
==Working Documents==<br />
<br />
*[[Media:COPDDensityMatrix-V3.xls|COPD Density Matrix V3]]<br />
<br />
*[[Media:COPDMorphologyMatrix-V1.xls|COPD Morphology Matrix V1]]<br />
<br />
<br />
==Reference Documents==<br />
<br />
<br />
*[[Media:06-21-2011GammexBoxFullPath.ppt|06-21-2011GammexBoxFullPath.ppt]] ''posted 6.23.2011''<br />
<br />
*[[Media:06-08-2011COPDGeneModel2-GammexBox.ppt|06-08-2011 COPDGeneModel2-GammexBox.ppt]] ''posted 6.8.2011''<br />
<br />
*[[Media:Madani - multi-slice cut off-20100421.pdf|Pulmonary Emphysema: Objective Quantification at Multi–Detector Row CT—Comparison with Macroscopic and Microscopic Morphometry]] Madani et al, Radiology: Volume 238: Number 3-March 2006<br />
<br />
*[[Media:Madani - Dose CT-3-20100421.pdf|Pulmonary Emphysema: Radiation Dose and Section Thickness at Multidetector CT Quantification—Comparison with Macroscopic and Microscopic Morphometry]] Madani et al, Radiology: Volume 243: Number 1-April 2007<br />
<br />
*[[Media:Imaging_Section_of_MOP.doc|COPDGene protocol section]]<br />
*[[Media:ECLIPSE-Protocol-ERJ.pdf|ECLIPSE protocol description]]<br />
*[[Media:CT_protocol-v3.doc|ECLIPSE CT protocol specifics]]<br />
*[[Media:Coxson-chairman's_summary.pdf|Coxson's chairman summary]]<br />
*[[Media:Structural_and_Functional_Assessment_of_the_Lung_Hoffman.pdf|Hoffman et al's paper on quantitative assessment]]<br />
*[[Media:Stoel2008PATS-volumecorrection.pdf|Stoel et al's paper on volume correction]]<br />
*[[Media:Stoel2008PATS-longitudinalstudies.pdf|Stoel et al's paper on longitudinal studies]]<br />
*[[Media:FDA-COPDGuidance-20100201.pdf|FDA Guidance for Industry - Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment]]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:3A_study_design_0.5.doc&diff=3244File:3A study design 0.5.doc2011-06-23T17:23:04Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=VolCT_-_Group_3A&diff=3243VolCT - Group 3A2011-06-23T17:22:06Z<p>Abuckler: </p>
<hr />
<div>==Meeting Preparation for Upcoming Webex Calls==<br />
*[[Media:3A study design 0.5.doc |QIBA Volumetric CT 3A Study Design, 0.5 (Word document)]] '' posted 6.23.2011 for review ''<br />
*[[Media:3A study design 0.4.doc |QIBA Volumetric CT 3A Study Design, 0.4 (Word document)]] '' posted 5.12.2011 for review ''<br />
*[[Media:3A study design-3.doc |QIBA Volumetric CT 3A Study Design (Word document)]] '' posted 4.28.2011 for review ''<br />
*[[Media:3A study design.doc|QIBA Volumetric CT 3A Study Design (Word document)]] '' posted 3.29.2011 for review ''<br />
<br />
<br />
*[[Media:6th meeting_member contribution.ppt|QIBA Volumetric CT 3A Member Comments (PowerPoint)]] '' posted 4.29.2011 for review ''<br />
*[[Media:Study Design.ppt|QIBA Volumetric CT 3A Study Design (PowerPoint)]] '' posted 3.29.2011 for review ''<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:QIBA Volumetric CT 3A Group meeting on 03.03.2011 PPT.pdf|QIBA Volumetric CT 3A PowerPoint slides from meeting on 03.03.2011]] '' posted 3.14.2011 ''<br />
*[[Media:QIBA Volumetric CT 3A Group first meeting-20110113.pdf|QIBA Volumetric CT 3A Group First Meeting]]<br />
<br />
<br />
<br />
==2011 Call Summaries==<br />
<br />
<br />
*[[Media:06.09.2011 QIBA VolCT Group 3A Call Summary-FINAL.pdf|06.09.2011 Vol-CT Group 3A Call Summary]]<br />
*[[Media:05.31.2011 QIBA Volumetric CT Group 3A call summary FINAL.pdf|05.31.2011 Vol-CT Group 3A Call Summary]]<br />
*[[Media:05.12.2011 QIBA Volumetric CT Group 3A call summary FINAL.pdf|05.12.2011 Vol-CT Group 3A Call Summary]]<br />
*[[Media:04.28.2011 QIBA Vol-CT Group 3A Subctte Summary-FINAL.pdf|04.28.2011 Vol-CT Group 3A Call Summary]]<br />
*[[Media:04.14.2011 QIBA Vol-CT Group 3A Subctte Summary-FINAL-2.pdf|04.14.2011 Vol-CT Group 3A Call Summary]]<br />
*[[Media:03.17.2011 QIBA Vol-CT Group 3A Subctte Summary-FINAL.pdf|03.17.2011 Vol-CT Group 3A Call Summary]]<br />
*[[Media:03.03.2011 QIBA Vol-CT Group 3A Subctte Summary-FINAL.pdf|03.03.2011 Vol-CT Group 3A Call Summary]]<br />
*[[Media:02.17.2011 QIBA Vol-CT Group 3A Subctte Summary-FINAL.pdf|02.17.2011 Vol-CT Group 3A Call Summary]]<br />
*[[Media:02.03.2011 QIBA Vol-CT Group 3A Subctte Summary-FINAL.pdf|02.03.2011 Vol-CT Group 3A Call Summary]]<br />
*[[Media:01.13.2011 QIBA Vol-CT Group 3A Subctte Summary-FINAL.pdf|01.13.2011 Vol-CT Group 3A Call Summary]]<br />
<br />
==WIKI help protocols==<br />
*[[Media:Microsoft Word-Wiki Protocol-v2.pdf|Using the WIKI]]<br />
*[[Media:Wiki Help-History Overview2.pdf|Using the WIKI to check history and compare documents]]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Public_Comment_Process&diff=3233Public Comment Process2011-06-22T13:25:45Z<p>Abuckler: </p>
<hr />
<div>Public Comment is intended to allow both regular participants in QIBA Activities and also those who don't have the time to dedicate to regular participation a chance to contribute their thoughts on proposed specifications before they are formally released. Comments are accepted from all.<br />
<br />
Public comment should be considered the prelude to publication. A committee should be largely satisfied with the contents of a document before it is sent out for Public Comment.<br />
<br />
Note in the description below that the "secretariat" is understood to be the RSNA. Specific tasks may be assigned to staff and/or contractors of RSNA in performance of the function.<br />
<br />
Period: 30 days<br />
<br />
* [[Review Process|Approve for public comment]] ('''Technical Committee''')<br />
* Post PC draft of Document on the Wiki ('''editor/secretariat''')<br />
* Send announcement to mailing lists ('''secretariat''')<br />
** detail location of document to be reviewed, deadline for comment submission, method of submission<br />
** provide a link to the [[:Media:QIBA_Public_Comment_Template-2011.01.doc | QIBA Public Comment Template]]<br />
* Email comments to secretariat ('''Commenters''')<br />
** commenters include committee members, other QIBA people, external bodies<br />
** this is the key point for asynchronous engagement<br />
** please use the provided comment form, it saves the editor having to transcribe your comments<br />
* Collate all comments into a spreadsheet ('''secretariat/editor''')<br />
** sort by line number and priority (Low/Med/High)<br />
* Resolve comments with priority Low ('''editor''')<br />
** if any Low comments prove problematic, elevate to Med<br />
* Review Med & High comments ('''Technical Committee''')<br />
** walk through document<br />
** each comment may be:<br />
*** accepted = proposed text accepted as is<br />
*** rejected = committee does not agree with issue (document reason, e.g. out of scope, )<br />
*** resolved = issue accepted but resolved differently than proposed<br />
* Record resolution in spreadsheet ('''editor''')<br />
* Post resolution spreadsheet and updated Document on the Wiki ('''editor/secretariat''')</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Public_Comment_Process&diff=3232Public Comment Process2011-06-22T13:24:53Z<p>Abuckler: </p>
<hr />
<div>Public Comment is intended to allow both regular participants in QIBA Activities and also those who don't have the time to dedicate to regular participation a chance to contribute their thoughts on proposed specifications before they are formally released. Comments are accepted from all.<br />
<br />
Public comment should be considered the prelude to publication. A committee should be largely satisfied with the contents of a document before it is sent out for Public Comment.<br />
<br />
Note in the description below that the "secretariat" is understood to be the RSNA. Specific tasks may be assigned to staff and/or contractors of RSNA in performance of the function.<br />
<br />
Period: 30 days<br />
<br />
* [[Review Process|Approve for public comment]] ('''Technical Committee''')<br />
* Post PC draft of Document on the Wiki ('''editor/secretariat''')<br />
* Send announcement to mailing lists ('''secretariat''')<br />
** detail location of document to be reviewed, deadline for comment submission, method of submission<br />
** provide a link to the [[:Media:QIBA_Public_Comment_Template-2011.01.doc | QIBA Public Comment Template]]<br />
* Email comments to secretariat ('''Commenters''')<br />
** commenters include committee members, other QIBA people, external bodies<br />
** this is the key point for asynchronous engagement<br />
** please use the provided comment form, it saves the author having to transcribe your comments<br />
* Collate all comments into a spreadsheet ('''secretariat/author''')<br />
** sort by line number and priority (Low/Med/High)<br />
* Resolve comments with priority Low ('''editor''')<br />
** if any Low comments prove problematic, elevate to Med<br />
* Review Med & High comments ('''Technical Committee''')<br />
** walk through document<br />
** each comment may be:<br />
*** accepted = proposed text accepted as is<br />
*** rejected = committee does not agree with issue (document reason, e.g. out of scope, )<br />
*** resolved = issue accepted but resolved differently than proposed<br />
* Record resolution in spreadsheet ('''editor''')<br />
* Post resolution spreadsheet and updated Document on the Wiki ('''editor/secretariat''')</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Review_Process&diff=3231Review Process2011-06-22T13:16:55Z<p>Abuckler: </p>
<hr />
<div>It's basically the same review process prior to releasing for Trial Implementation or Publication (and if we want to be good, before Public Comment). <br />
<br />
Remember, this is the QA point. It doesn't have to be perfect. '''It does have to be good'''.<br />
<br />
==Review and Approval==<br />
* Judge the document to be fit for the next phase (Technical Committee''')<br />
** Schedule review meeting(s) as needed with open committee<br />
** Submit document 1 week before review meeting<br />
** Line-by-line review/walkthrough led by editor<br />
** Resolve questions/comments/clarifications<br />
** Record vote to approve the document as fit for the next phase (as quorum of regular attender list maintained by RSNA staff)<br />
<br />
===Criteria for Public Comment===<br />
* All open issues have been clearly listed<br />
* Some groundwork projects may be underway<br />
* Candidate resolutions have been selected for most/all issues and drafted into the Profile<br />
* All major mechanisms and profile details are mostly clear/complete enough to implement<br />
* It is clear what is required for a system/organization to claim compliance with the Profile<br />
* Compliance requirements are sufficient to accomplish the goal of the profile<br />
<br />
===Criteria for Trial Implementation===<br />
* Few, if any, groundwork projects remain active<br />
* All major mechanisms and profile details are clear/complete enough to implement<br />
* It is clear what is required for a system/organization to claim compliance with the Profile<br />
* Compliance requirements are sufficient to accomplish the goal of the profile<br />
<br />
===Criteria for Publication===<br />
* All open issues have been resolved<br />
* All major mechanisms and profile details have been tested in the field<br />
* Groundwork projects are complete<br />
* All major mechanisms and profile details are clear/complete enough to implement<br />
* It is clear what is required for a system/organization to claim compliance with the Profile<br />
* Compliance requirements are sufficient to accomplish the goal of the profile</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=FDG-PET_Biomarker_Ctte&diff=3144FDG-PET Biomarker Ctte2011-05-11T18:59:46Z<p>Abuckler: </p>
<hr />
<div>== Quantitative FDG-PET Technical Committee Mission ==<br />
<br />
*'''Mission; Foster adoption of ...'''<br />
**pragmatic and cost effective standards for<br />
**accurate and reproducible<br />
**longitudinal<br />
**quantitation of<br />
**biologic parameters<br />
**with clinical relevance<br />
**and known sigma<br />
<br />
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
<br />
==Meetings / Call Summaries==<br />
*[[Monthly FDG-PET Call Summaries]]<br />
<br />
<br />
<br />
==UPICT Protocol Development==<br />
<br />
*[[Media:UPICT FDG Consolidated Statement post call 05032011-1.doc|UPICT Consolidated Statement-Post Call 05-03-2011]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* [[Media: Profile_FDG-PET_0419011.doc|Whole Body FDG-PET]] ''Word version of Profile applicable to multiple indications, 04-19-2011''<br />
Archive:<br />
* [[Media: Profile_FDG-PET_03122011.doc|Whole Body FDG-PET]] ''Word version of Profile applicable to multiple indications, 03-12-2011''<br />
* [[Profile: FDG-PET Whole Body]] ''First version of Profile, 2009 (currently inactive)''<br />
<br />
==Working Documents and Reference Materials==<br />
*[[Covariates Rationale]]<br />
*[[Standardized Uptake Value (SUV)]]<br />
*[[Quality Control Metrics]]<br />
*[[ROI Definition]]<br />
*[[Software Version Tracking]]<br />
<br />
*[[Media:PET-CovariatesRationale YAP 20090310.ppt|Covariates Rationale SubCtte]] ''March 2009''<br />
*[[Media:PET-DRO KINAHAN 2009-03-10.ppt|Digital Reference Objects SubCtte]] ''March 2009''<br />
*[[Media:PET-QualityControlMetrics YAP 20090224.ppt|Quality Control Metrics SubCtte]] ''March 2009''<br />
*[[Media:PET-ROI-Definitions TURKINGTON 20090306.ppt|Region of Interest SubCtte]] ''March 2009''<br />
*[[Media:PET-SoftwareVersionTracking SHAO 3-13-09-2.ppt|Software Version Tracking SubCtte]] ''March 2009''<br />
<br />
*[[Media:Boellaard-Aanbevelingen NEDPAS 2007 - EN- 17032009.pdf|NL Standardization Protocol for Quantitative FDG-PET in multi-Center Trials - Dr Ronald Boellaard]]<br />
<br />
'''The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)'''<br />
<br />
Please keep the following in mind:<br />
<br />
The development of this protocol was started about 2005 and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):<br />
<br />
*Use of oral contrast is now excluded but will be allowed in the next version<br />
*We are currently working on standards for CT as well, including GL for doing CT-QC (in cooperation with the radiologists/radiology societies in NL)<br />
*There will be an upper limit for dosage<br />
*We are working on traceable/calibrated and mutually linked sources for both PET and the dose calibrator and these will be used for absolute (rather than cross-) calibration (but in addition to the cross-calibration using FDG).<br />
*Reconstruction settings given in the protocol are indicative and are likely not applicable for future scanners and software upgrades. Therefore reconstruction parameters should be set such that they provide results that meet the specifications given for the multi-center QC experiments. Same settings should then be applied to patient studies (see also comments under "execptions/special features” and comments made in the paper by Boellaard et al. EJNMMI 2008).<br />
* Various other minor edits/typos/changes<br />
<br />
The protocol is not a step-by-step description of the logistics for doing a PET/CT study. However, it has been set up in a somewhat chronological order and may thus be used to populate (copy-paste) such a step-by-step description. Additional work required ... FDG-PET/CT Technical Committee input is highly appreciated.<br />
<br />
Submitted by Ronald Boellaard, PhD<br />
<br /><br />
*[[Media:Wahl PERCIST JNM 2009.pdf|From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors]]<br />
Submitted by Richard L. Wahl, MD and Martin A. Lodge, PhD<br />
<br />
*[[Media:05.19.2009 QIBA FDG-PET Breakout Session Notes.pdf|05.19.2009 QIBA FDG-PET/CT Breakout Session Notes]]<br />
<br />
*[[Media:QIBA FDGPET ICL.imageanalysis-Dr-Perlman-20090617.pdf|Draft FDG-PET ICL Logistics Outline]]<br />
Submitted by Eric S. Perlman, MD<br />
<br />
*[[Media:SUV for PET Paper.pdf|Reevaluation of the Standardized Uptake Value for FDG: Variations with Body Weight and Methods for Correction - ''Radiology'' 1999; 213: 521-525]]<br />
<br />
==Slide Presentations==<br />
*[[QIBA Informational Meeting (Dec 1st at RSNA 2008) - Slide Content Review]]<br />
*[[Media:Dr Frank Breakout + PETCT Tech Cmte 081204.ppt|QIBA Working Meeting (Dec 4th at RSNA 2008) - FDG-PET/CT Breakout Session Slide Deck]]<br />
*[[Fused Images]]<br />
*[[Media:FDG-PET11-29.ppt]]<br />
*[[Media:Mission FDG PETCT Tech Cmte 080520-DR-FRANK-20090310.ppt|QIBA FDG-PET/CT Mission Statement - 2009.03.10]]<br />
*[[Media:ProfilingSlides-ABuckler-20090331.pdf|QIBA Profiling Process-03.31.2009 (Andrew Buckler, MS)]]<br />
*[[Media:Frank-FDG-PET-20090520.ppt|FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank]]<br />
<br />
<br />
==Round 1 of QIBA Funded Projects==<br />
<br />
*[[VU University Medical Center, The Netherlands]]<br />
<br />
*[[University of Washington]]<br />
<br />
*[[Johns Hopkins University School of Medicine]]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=FMRI_Biomarker_Ctte&diff=3143FMRI Biomarker Ctte2011-05-11T18:56:36Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
<br />
<br />
==Meetings/Call Summaries==<br />
*[[fMRI Call Summaries]]<br />
<br />
<br />
==Working Documents==<br />
<br />
*[[Media:Draft fMRI_Profile_v0.1.doc|QIBA Profile for Brain Mapping - Draft - v0.1]]<br />
*[[Media:Draft fMRI_Protocol_v0.1.doc|UPICT Protocol for Brain Mapping - Draft - v0.1]]<br />
*[[Media:Draft QIBA profile for fMRI brain mapping EAD JP 20100624.doc|QIBA Profile for Brain Mapping - Draft - 06.24.2010]] ''Dr Elsinger''<br />
*[[Media:Draft QIBA profile for fMRI brain mapping PETRELLA 20100601.doc|QIBA Profile for Brain Mapping - Draft - 06.01.2010]] ''Dr Petrella''<br />
*[[Media:Draft QIBA profile for fMRI brain mapping EAD.CE 05 05 10-2.doc|QIBA Profile for Brain Mapping - Draft - 05.05.2010-2]] ''Dr DeYoe''<br />
*[[Media:Draft QIBA profile for fMRI brain mapping EAD 05 05 10.doc|QIBA Profile for Brain Mapping - Draft - 05.05.2010]] ''Dr DeYoe''<br />
*[[Media:INTENDED USE-QIBA Profile Draft.04.20.2010-DrPetrella.doc|Profile Intended Use Draft Statement - 04.20.2010]] ''Dr Petrella''<br />
*[[Media:INTENDED USE-QIBA Profile Draft.04.20.2010-DrElsinger.doc|Profile Intended Use Draft Statement - 04.20.2010]] ''Dr Elsinger''<br />
<br />
*[[Media:QIBA fMRI Subcommittee Profile Draft 4.08.10 DrReuss.doc|fMRI Profile Draft - 04.08.2010]] ''Dr Reuss''<br />
*[[Media:QIBA fMRI Subcommittee Profile Draft 4.06.10.doc|fMRI Profile Draft - 04.06.2010]] ''Dr Elsinger''<br />
*[[Media:QIBA fMRI Subcommittee Profile Draft 3.22.10.doc|fMRI Profile Draft - 03.22.2010]] ''Dr Elsinger''<br />
<br />
* [[Profile Development]]<br />
<br />
<br />
==Workflow Documents==<br />
<br />
<br />
*[[Media:QIBAWorkflowChecklistJV.xls|QIBA fMRI Workflow Checklist]] ''Dr Voyvodic 11.11.2010''<br />
*[[Media:DeYoe workflow-20101004.doc|Workflow - Dr. DeYoe - October 2010]]<br />
*[[Media:Clinical fMRI Workflow and Data 2010.NNL.CE.QIBA-1.doc|Workflow - Dr. Elsinger - October 2010]]<br />
*[[Media:Reuss Prism fMRI workflow 20100930.doc|Workflow - Dr. Reuss - September 2010]]<br />
*[[Media:Clinical fMRI Workflow and Data 2010-05-18 MNI.pdf|Workflow - Dr. Tucker - July 2010]]<br />
*[[Media:Duke Workflow for May 2010 Mtg.doc|Workflow - Drs Voyvodic and Petrella - May 2010]]<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:DrTuckerSlides 2010 11 WG16.ppt -Compatibility M.pdf|Dr. Tucker's DICOM Work Group 16 Slide Set - Nov 2010]]<br />
<br />
*[[Media:FMRI Reproducibility071410.pdf|fMRI Reproducibility Study]] ''Dr Voyvodic - 07-14-2010''<br />
<br />
*[[Media:FMRI Subctte ReportOut-QIBA2010.ppt|fMRI SubCtte Breakout Session Report at QIBA 2010 - 05.26.2010]]<br />
<br />
*[[Media:American Academy of Neurology Classification of Evidence-20100504.doc|American Academy of Neurology Classification of Evidence]]<br />
<br />
*The QIBA wiki has background information on Profiles and their development - [http://qibawiki.rsna.org/index.php?title=Main_Page What are Profile? How does QIBA Derive Profiles?]<br />
<br />
*Examples of CT Profiles are also posted on the QIBA wiki - [http://qibawiki.rsna.org/index.php?title=Quantitative-CT Quantitative CT Profiles]<br />
<br />
*Protocol template by UPICT (Uniform Protocols in Clinical Trials) - [http://upictwiki.ctsa-imaging.org/index.php?title=UPICT_Template UPICT Template]<br />
<br />
*The Profile: [http://qibawiki.rsna.org/index.php?title=Profile:_CT_Lung_Nodule_Volume_Measurement_for_Primary/Regional_Nodes_and_Metastatic_Sites CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites] uses the UPICT template as a structure.<br />
<br />
*[[Media:ACR fMRI Clinical Guidelines.pdf|ACR fMRI Clinical Guidelines]]<br />
*[[Media:Bizzi et al Radiology 2008-20100210.pdf|Bizzi A, et al. '''Presurgical Functional MR Imaging of Language and Motor Functions: Validation with Intraoperative Electrocortical Mapping.''' Radiology 2008; 248:579-589]]<br />
<br />
*[[Media:DrMohamed-Price etal 2010-20100420.pdf|The anatomy of language: a review of 100 fMRI studies published in 2009, Cathy J. Price (Ann. N.Y. Acad. Sci. ISSN 0077-8923)]] ''Posted 04.20.2010''<br />
<br />
==fMRI Poster for RSNA 2010==<br />
<br />
*[[Media:RSNA QIBA fMRI SCposter2010.V2.ppt|RSNA 2010 QIBA fMRI SubCtte Poster - V2]] ''Posted 10.26.2010''<br />
<br />
==PubMed Search Strategy==<br />
<br />
<br />
'''Search topic: fMRI in Presurgical Brain Mapping'''<br />
<br />
"Brain Mapping"[Mesh] AND "Magnetic Resonance Imaging"[Mesh] AND (functional[All Fields] OR "fmri"[All Fields]) AND (presurgical[All Fields] OR "Preoperative Care"[Mesh] OR "Surgery, Computer-Assisted"[Mesh]) AND ("humans"[MeSH Terms] AND English[lang])<br />
<br />
<br />
<br />
[http://www.ncbi.nlm.nih.gov/pubmed?term=%22Brain%20Mapping%22%5BMesh%5D%20AND%20%22Magnetic%20Resonance%20Imaging%22%5BMesh%5D%20AND%20%28functional%5BAll%20Fields%5D%20OR%20%22fmri%22%5BAll%20Fields%5D%29%20AND%20%28presurgical%5BAll%20Fields%5D%20OR%20%22Preoperative%20Care%22%5BMesh%5D%20OR%20%22Surgery%2C%20Computer-Assisted%22%5BMesh%5D%29%20AND%20%28%22humans%22%5BMeSH%20Terms%5D%20AND%20English%5Blang%5D%29&cmd=DetailsSearch fMRI in Presurgical Brain Mapping - Click for PubMed search results]<br />
<br />
<br />
==fMRI-DICOM Work Group==<br />
<br />
* [[fMRI-DICOM WG Call Summaries]]<br />
<br />
<br />
<br />
==fMRI Reproducibility Work Group==<br />
<br />
*[[Media:04.26.2011 QIBA fMRI Reproducibility Call Summary-FINAL.pdf|04.26.2011 QIBA fMRI Reproducibility Work group Call Summary]]<br />
*[[Media:03.15.2011 QIBA fMRI Reproducibility Call Summary-FINAL.pdf|03.15.2011 QIBA fMRI Reproducibility Work group Call Summary]]<br />
*[[Media:03 01 2011 QIBA fMRI Reproducibility call summary FINAL.pdf|03.01.2011 QIBA fMRI Reproducibility Work Group Call Summary]]<br />
*[[Media:02 15 2011 QIBA fMRI Reproducibility call summary FINAL.pdf|02.15.2011 QIBA fMRI Reproducibility Work Group Call Summary]]<br />
*[[Media:02 01 2011 QIBA fMRI Reproducibility call summary FINAL2.pdf|02.01.2011 QIBA fMRI Reproducibility Work Group Call Summary]]<br />
*[[Media:01 11 2011 QIBA fMRI Reproducibility call summary FINAL.pdf|01.11.2011 QIBA fMRI Reproducibility Work Group Call Summary]]<br />
*[[Media:12 21 2010 QIBA fMRI Reproducibility call summary FINAL.pdf|12.21.2010 QIBA fMRI Reproducibility Work Group Call Summary]]<br />
*[[Media:11.02.2010 QIBA fMRI Reproducibility WG Call Summary-FINAL.pdf|11.02.2010 QIBA fMRI Reproducibility Work Group Call Summary]]<br />
*[[Media:10.19.2010 QIBA fMRI Reproducibility-call summary-FINAL.pdf|10.19.2010 QIBA fMRI Reproducibility Work Group Call Summary]]<br />
*[[Media:10.05.10 QIBA fMRI Reproducibility WG Call Summary-FINAL.pdf|10.05.2010 QIBA fMRI Reproducibility Work Group Call Summary]]<br />
<br />
==Round 1 of QIBA Funded Projects==<br />
*[[Duke Brain Imaging and Analysis Center]]<br />
*[[Medical College of Wisconsin]]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.05.05.Profile_CT_advanced_disease_V1_9.doc&diff=3142File:2011.05.05.Profile CT advanced disease V1 9.doc2011-05-11T18:54:32Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=3141CT Volumetry Biomarker Ctte2011-05-11T18:53:28Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.05.05.Profile_CT_advanced_disease_V1_9.doc|Advanced Disease Profile v1.9 post call]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems'' ''05/05/2011''<br />
** [[Media: 2011.03.27.Profile_CT_advanced_disease_V1_7 post call.doc|Advanced Disease Profile v1.7 post call]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems'' ''03/27/2011''<br />
** [[Media: 2011.03.27.Protocol_CT_advanced_disease_V1_7.doc|Advanced Disease Protocol v1.7]] ''UPICT Protocol'' ''03/27/2011''<br />
* Small nodule:<br />
** [[Media: 2011.04.09_Profile_CT_small_nodule_V0_7.doc|Small Nodule Profile v0.7]] ''Profile applicable to small pulmonary nodules'' '' 04/09/2011''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*Advanced Disease:<br />
** [[Media:2011.02.28.Profile CT advanced disease V1 6.doc|VIA Profile v1.6]] ''02/28/2011''<br />
** [[Media:2011.01.09.QIBA VIA Profile V1 5.doc|VIA Profile v1.5]] ''01/09/2011''<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
*Small Nodule:<br />
** [[Media:2011.03.12 Profile CT small nodule V0 6.doc|Small Pulmonary Nodule Profile v0.6]] ''03/12/2011''<br />
** [[Media:2011.02.14 Profile CT early disease V0 4.doc|Small Pulmonary Nodule Profile v0.4]] ''02/14/2011''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]<br />
<br />
==Round 1 of QIBA Funded Projects==<br />
*[[TBN]]<br />
*[[Duke University]]<br />
*[[Columbia University Medical Center]]<br />
*[[University of Colorado Denver, Department of Radiology]]<br />
*[[David Geffen School of Medicine at UCLA, Department of Radiology]]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.04.09_Profile_CT_small_nodule_V0_7.doc&diff=3013File:2011.04.09 Profile CT small nodule V0 7.doc2011-04-11T17:46:03Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=3012CT Volumetry Biomarker Ctte2011-04-11T17:44:55Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.03.27.Profile_CT_advanced_disease_V1_7 post call.doc|Advanced Disease Profile v1.7 post call]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.03.27.Protocol_CT_advanced_disease_V1_7.doc|Advanced Disease Protocol v1.7]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.04.09_Profile_CT_small_nodule_V0_7.doc|Small Nodule Profile v0.7]] ''Profile applicable to small pulmonary nodules''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]<br />
<br />
==Round 1 of QIBA Funded Projects==<br />
*[[TBN]]<br />
*[[Duke University Medical Center]]<br />
*[[Columbia University Medical Center]]<br />
*[[University of Colorado Denver, Department of Radiology]]<br />
*[[David Geffen School of Medicine at UCLA, Department of Radiology]]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.03.27.Profile_CT_advanced_disease_V1_7_post_call.doc&diff=2903File:2011.03.27.Profile CT advanced disease V1 7 post call.doc2011-03-28T19:01:50Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2902CT Volumetry Biomarker Ctte2011-03-28T19:01:37Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.03.27.Profile_CT_advanced_disease_V1_7 post call.doc|Advanced Disease Profile v1.7 post call]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.03.27.Protocol_CT_advanced_disease_V1_7.doc|Advanced Disease Protocol v1.7]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.03.12_Profile_CT_small_nodule_V0_6_post_call.doc|Small Nodule Profile v0.6]] ''Post-call Profile applicable to small pulmonary nodules''<br />
** [[Media: 2011.03.12_UPICT_CT_small_nodule_V0_6.doc|Small Nodule Protocol v0.6]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.03.27.Protocol_CT_advanced_disease_V1_7.doc&diff=2901File:2011.03.27.Protocol CT advanced disease V1 7.doc2011-03-27T22:13:45Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.03.27.Profile_CT_advanced_disease_V1_7.doc&diff=2900File:2011.03.27.Profile CT advanced disease V1 7.doc2011-03-27T22:13:25Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2899CT Volumetry Biomarker Ctte2011-03-27T22:12:30Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.03.27.Profile_CT_advanced_disease_V1_7.doc|Advanced Disease Profile v1.7]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.03.27.Protocol_CT_advanced_disease_V1_7.doc|Advanced Disease Protocol v1.7]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.03.12_Profile_CT_small_nodule_V0_6_post_call.doc|Small Nodule Profile v0.6]] ''Post-call Profile applicable to small pulmonary nodules''<br />
** [[Media: 2011.03.12_UPICT_CT_small_nodule_V0_6.doc|Small Nodule Protocol v0.6]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2898CT Volumetry Biomarker Ctte2011-03-27T22:11:58Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.03.27.Profile_CT_advanced_disease_V1_7.doc|VIA Profile v1.7]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.03.27.Protocol_CT_advanced_disease_V1_7.doc|VIA Protocol v1.7]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.03.12_Profile_CT_small_nodule_V0_6_post_call.doc|Small Nodule Profile v0.6]] ''Post-call Profile applicable to small pulmonary nodules''<br />
** [[Media: 2011.03.12_UPICT_CT_small_nodule_V0_6.doc|Small Nodule Protocol v0.6]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.03.12_Profile_CT_small_nodule_V0_6_post_call.doc&diff=2888File:2011.03.12 Profile CT small nodule V0 6 post call.doc2011-03-20T12:18:24Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2887CT Volumetry Biomarker Ctte2011-03-20T12:17:57Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.02.28.Profile_CT_advanced_disease_V1_6.doc|VIA Profile v1.6]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.02.28.Protocol_CT_advanced_disease_V1_6.doc|VIA Protocol v1.6]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.03.12_Profile_CT_small_nodule_V0_6_post_call.doc|Small Nodule Profile v0.6]] ''Post-call Profile applicable to small pulmonary nodules''<br />
** [[Media: 2011.03.12_UPICT_CT_small_nodule_V0_6.doc|Small Nodule Protocol v0.6]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:Protocol_V0_2_Asthma_COPD_03192011.doc&diff=2886File:Protocol V0 2 Asthma COPD 03192011.doc2011-03-20T12:16:04Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:Profile_V0_2_Asthma_COPD_03192011.doc&diff=2885File:Profile V0 2 Asthma COPD 03192011.doc2011-03-20T12:15:45Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Lung_Density_Biomarker_Ctte&diff=2884Lung Density Biomarker Ctte2011-03-20T12:14:49Z<p>Abuckler: </p>
<hr />
<div>__NOTOC__<br />
This Wiki is for collaborative creation of QIBA's Chronic Obstructive Pulmonary Disease (COPD) and Asthma Committee materials and ongoing activities.<br />
<br />
<br />
'''Mission''': Reduce and characterize bias and variance across manufacturers, versions, and sites in support of quantitative CT lung densitometry and morphology. <br />
<br />
'''Initial Objectives''':<br />
:* Characterize the precision and accuracy of phenotyping and progression measurements in emphysema and asthma. <br />
:: This is an essential effort to classify phenotype and assess longitudinal changes as medically meaningful surrogates for health status. <br />
:* Compare the sensitivity of CT measurements to spirometry and other accepted measures. <br />
:: This will be necessary in order to determine if Progressive Disease can be detected significantly sooner with quantitative imaging techniques than with currently accepted methods.<br />
<br />
<br />
==Profiling Activities==<br />
<br />
* [[Media:Profile_V0_2_Asthma_COPD_03192011.doc|COPD QIBA Profile v0.2]]<br />
* [[Media:Protocol_V0_2_Asthma_COPD_03192011.doc|COPD UPICT Protocol v0.2]]<br />
<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
<br />
* [[Claim Language/Detail]]<br />
<br />
==Protocol Development Activities==<br />
<br />
*[http://upictwiki.ctsa-imaging.org/index.php?title=UPICT_Template UPICT Template]<br />
<br />
==Groundwork Activities==<br />
Validate key concepts and answer key questions needed to write the Profiles and demonstrate their effectiveness.<br />
<br />
* Phantom project<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[COPD Group Call Summaries]]<br />
<br />
<br />
==Working Documents==<br />
<br />
*[[Media:COPDDensityMatrix-V3.xls|COPD Density Matrix V3]]<br />
<br />
*[[Media:COPDMorphologyMatrix-V1.xls|COPD Morphology Matrix V1]]<br />
<br />
<br />
==Reference Documents==<br />
<br />
*[[Media:Madani - multi-slice cut off-20100421.pdf|Pulmonary Emphysema: Objective Quantification at Multi–Detector Row CT—Comparison with Macroscopic and Microscopic Morphometry]] Madani et al, Radiology: Volume 238: Number 3-March 2006<br />
<br />
*[[Media:Madani - Dose CT-3-20100421.pdf|Pulmonary Emphysema: Radiation Dose and Section Thickness at Multidetector CT Quantification—Comparison with Macroscopic and Microscopic Morphometry]] Madani et al, Radiology: Volume 243: Number 1-April 2007<br />
<br />
*[[Media:Imaging_Section_of_MOP.doc|COPDGene protocol section]]<br />
*[[Media:ECLIPSE-Protocol-ERJ.pdf|ECLIPSE protocol description]]<br />
*[[Media:CT_protocol-v3.doc|ECLIPSE CT protocol specifics]]<br />
*[[Media:Coxson-chairman's_summary.pdf|Coxson's chairman summary]]<br />
*[[Media:Structural_and_Functional_Assessment_of_the_Lung_Hoffman.pdf|Hoffman et al's paper on quantitative assessment]]<br />
*[[Media:Stoel2008PATS-volumecorrection.pdf|Stoel et al's paper on volume correction]]<br />
*[[Media:Stoel2008PATS-longitudinalstudies.pdf|Stoel et al's paper on longitudinal studies]]<br />
*[[Media:FDA-COPDGuidance-20100201.pdf|FDA Guidance for Industry - Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment]]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:HHSN268201000050C_QIBA_Semiannual_Report_3-11-2010.doc&diff=2855File:HHSN268201000050C QIBA Semiannual Report 3-11-2010.doc2011-03-13T12:37:28Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Main_Page&diff=2854Main Page2011-03-13T12:36:58Z<p>Abuckler: </p>
<hr />
<div>__NOTOC__<br />
This Wiki is for collaborative creation of QIBA materials and ongoing activities.<br />
<br />
='''Quantitative Imaging Biomarkers Alliance (QIBA)'''=<br />
<br />
'''QIBA Mission: Improve the value and practicality of quantitative biomarkers by reducing variability across devices, patients and time.'''<br />
<br />
<br />
QIBA is an initiative to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice by engaging researchers, healthcare professionals and industry . This involves:<br />
<br />
:* collaborating to identify needs, barriers, and solutions to develop and test consistent, reliable, valid, and achievable quantitative imaging results across imaging platforms, clinical sites, and time.<br />
:* accelerating the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.<br />
<br />
<br />
QIBA develops Profile specifications and coordinates the necessary research and qualification groundwork.<br />
:* [[What Are Profiles?]]<br />
:* [[Media:Profiling.ppt|How Does QIBA Derive Profiles?]]<br />
<br />
==QIBA Committees==<br />
QIBA currently has four active committees:<br />
:* [[Quantitative-MRI]]<br />
:**[[DCE-MRI subctte]]<br />
:**[[fMRI subctte]]<br />
:* [[Quantitative-PET]]<br />
:* [[Quantitative-CT]]<br />
:* [[COPD-Asthma]]<br />
<br />
==Documents==<br />
*[[Media:HHSN268201000050C_QIBA_Semiannual_Report_3-11-2010.doc|QIBA 1H-FY2011 Semi-annual Report (2011.03.11)]]<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_MR_specifics.pdf|"Why QIBA?" - Specifics associated with MR device and software manufacturers.]]<br />
*[[Media:HHSN268201000050C_QIBA_Proposed_Workplan_11-22-2010.doc|QIBA Work Plan (2010.11.22)]]<br />
*[[QIBA and UPICT posters from RSNA 2010 Annual Meeting]]<br />
*[[QIBA and UPICT posters from RSNA 2009 Annual Meeting]]<br />
*[[Media:EU.2009.08.04 Guideline on Clinical evaluation of diagnostic agents.pdf|EMEA Guideline on Clinical Evaluation of Diagnostic Agents (2009.08.04)]]<br />
*[[Media:EU.2009.08.04 Appendix 1 to the guideline.pdf|EMEA Guideline - Appendix 1 (2009.08.04)]]<br />
*[[Media:Oncology section.ppt|Oncology section from 2009 Imaging Biomarkers Roundtable]]<br />
*[[Media:FREEMAN_FINAL_PROOF.pdf|QIBA posters from RSNA 2008 Annual Meeting]]<br />
<br />
==Ad Hoc Committees==<br />
:*[[Committee on Open Image Archives]]<br />
<br />
----<br />
<br />
==Quantitative Imaging/Imaging Biomarkers and QIBA Meetings and Activities==<br />
*QI/IB Special Interest Session-<br />
Imaging Biomarkers for Clinical Care and Research<br />
Monday, November 29, 2010<br />
'''[http://www2.rsna.org/re/QI_IB_Special_Interest_Session_RSNA_2010/Index.htm Presentations]'''<br />
<br />
*SAVE-THE-DATE<br />
QIBA Annual Meeting<br />
May 24-25, 2011<br />
Renaissance Arlington Capital View, Arlington VA<br />
<br />
----<br />
<br />
NEW: '''[[How To's| "How To" help pages]]'''<br />
<br />
*[[Media:Enabling E-alerts-20100504.pdf|Enabling E-alerts]]<br />
<br />
*[[Media:Microsoft Word - WIKI PROTOCOL-v2.pdf|Posting Material]]<br />
<br />
*[[Media:Wiki Help-History Overview2.pdf|History Search]]<br />
<br />
'''''<This Wiki is a Work In Progress: read [[Help:Contents|Help]], create an [[Wiki Accounts|account]], contribute>'''''</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Main_Page&diff=2853Main Page2011-03-13T12:36:07Z<p>Abuckler: </p>
<hr />
<div>__NOTOC__<br />
This Wiki is for collaborative creation of QIBA materials and ongoing activities.<br />
<br />
='''Quantitative Imaging Biomarkers Alliance (QIBA)'''=<br />
<br />
'''QIBA Mission: Improve the value and practicality of quantitative biomarkers by reducing variability across devices, patients and time.'''<br />
<br />
<br />
QIBA is an initiative to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice by engaging researchers, healthcare professionals and industry . This involves:<br />
<br />
:* collaborating to identify needs, barriers, and solutions to develop and test consistent, reliable, valid, and achievable quantitative imaging results across imaging platforms, clinical sites, and time.<br />
:* accelerating the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.<br />
<br />
<br />
QIBA develops Profile specifications and coordinates the necessary research and qualification groundwork.<br />
:* [[What Are Profiles?]]<br />
:* [[Media:Profiling.ppt|How Does QIBA Derive Profiles?]]<br />
<br />
==QIBA Committees==<br />
QIBA currently has four active committees:<br />
:* [[Quantitative-MRI]]<br />
:**[[DCE-MRI subctte]]<br />
:**[[fMRI subctte]]<br />
:* [[Quantitative-PET]]<br />
:* [[Quantitative-CT]]<br />
:* [[COPD-Asthma]]<br />
<br />
==Documents==<br />
<br />
*[[Media:HHSN268201000050C_QIBA_Semiannual_Report_3-11-2010.doc|QIBA 1H-FY2011 Semi-annual Report (2011.03.11)]]<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_MR_specifics.pdf|"Why QIBA?" - Specifics associated with MR device and software manufacturers.]]<br />
*[[Media:HHSN268201000050C_QIBA_Proposed_Workplan_11-22-2010.doc|QIBA Work Plan (2010.11.22)]]<br />
*[[QIBA and UPICT posters from RSNA 2010 Annual Meeting]]<br />
*[[QIBA and UPICT posters from RSNA 2009 Annual Meeting]]<br />
*[[Media:EU.2009.08.04 Guideline on Clinical evaluation of diagnostic agents.pdf|EMEA Guideline on Clinical Evaluation of Diagnostic Agents (2009.08.04)]]<br />
*[[Media:EU.2009.08.04 Appendix 1 to the guideline.pdf|EMEA Guideline - Appendix 1 (2009.08.04)]]<br />
*[[Media:Oncology section.ppt|Oncology section from 2009 Imaging Biomarkers Roundtable]]<br />
*[[Media:FREEMAN_FINAL_PROOF.pdf|QIBA posters from RSNA 2008 Annual Meeting]]<br />
<br />
----<br />
<br />
==Ad Hoc Committees==<br />
<br />
:*[[Committee on Open Image Archives]]<br />
<br />
----<br />
<br />
==Quantitative Imaging/Imaging Biomarkers and QIBA Meetings and Activities==<br />
*QI/IB Special Interest Session-<br />
Imaging Biomarkers for Clinical Care and Research<br />
Monday, November 29, 2010<br />
'''[http://www2.rsna.org/re/QI_IB_Special_Interest_Session_RSNA_2010/Index.htm Presentations]'''<br />
<br />
*SAVE-THE-DATE<br />
QIBA Annual Meeting<br />
May 24-25, 2011<br />
Renaissance Arlington Capital View, Arlington VA<br />
<br />
----<br />
<br />
NEW: '''[[How To's| "How To" help pages]]'''<br />
<br />
*[[Media:Enabling E-alerts-20100504.pdf|Enabling E-alerts]]<br />
<br />
*[[Media:Microsoft Word - WIKI PROTOCOL-v2.pdf|Posting Material]]<br />
<br />
*[[Media:Wiki Help-History Overview2.pdf|History Search]]<br />
<br />
'''''<This Wiki is a Work In Progress: read [[Help:Contents|Help]], create an [[Wiki Accounts|account]], contribute>'''''</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Main_Page&diff=2852Main Page2011-03-13T12:34:16Z<p>Abuckler: </p>
<hr />
<div>__NOTOC__<br />
This Wiki is for collaborative creation of QIBA materials and ongoing activities.<br />
<br />
='''Quantitative Imaging Biomarkers Alliance (QIBA)'''=<br />
<br />
'''QIBA Mission: Improve the value and practicality of quantitative biomarkers by reducing variability across devices, patients and time.'''<br />
<br />
<br />
QIBA is an initiative to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice by engaging researchers, healthcare professionals and industry . This involves:<br />
<br />
:* collaborating to identify needs, barriers, and solutions to develop and test consistent, reliable, valid, and achievable quantitative imaging results across imaging platforms, clinical sites, and time.<br />
:* accelerating the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.<br />
<br />
<br />
QIBA develops Profile specifications and coordinates the necessary research and qualification groundwork.<br />
:* [[What Are Profiles?]]<br />
:* [[Media:Profiling.ppt|How Does QIBA Derive Profiles?]]<br />
<br />
==QIBA Committees==<br />
QIBA currently has four active committees:<br />
:* [[Quantitative-MRI]]<br />
:**[[DCE-MRI subctte]]<br />
:**[[fMRI subctte]]<br />
:* [[Quantitative-PET]]<br />
:* [[Quantitative-CT]]<br />
:* [[COPD-Asthma]]<br />
<br />
==Documents==<br />
<br />
*[[Media:HHSN268201000050C_QIBA_Semiannual_Report_3-11-2010.doc|QIBA 1H-FY2011 Semi-annual Report (2011.03.11)]]<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_MR_specifics.pdf|"Why QIBA?" - Specifics associated with MR device and software manufacturers.]]<br />
*[[Media:HHSN268201000050C_QIBA_Proposed_Workplan_11-22-2010.doc|QIBA Work Plan (2010.11.22)]]<br />
*[[Media:EU.2009.08.04 Guideline on Clinical evaluation of diagnostic agents.pdf|EMEA Guideline on Clinical Evaluation of Diagnostic Agents (2009.08.04)]]<br />
*[[Media:EU.2009.08.04 Appendix 1 to the guideline.pdf|EMEA Guideline - Appendix 1 (2009.08.04)]]<br />
*[[Media:Oncology section.ppt|Oncology section from 2009 Imaging Biomarkers Roundtable]]<br />
*[[Media:FREEMAN_FINAL_PROOF.pdf|QIBA posters from RSNA 2008 Annual Meeting]]<br />
*[[QIBA and UPICT posters from RSNA 2009 Annual Meeting]]<br />
*[[QIBA and UPICT posters from RSNA 2010 Annual Meeting]]<br />
<br />
----<br />
<br />
==Ad Hoc Committees==<br />
<br />
:*[[Committee on Open Image Archives]]<br />
<br />
----<br />
<br />
==Quantitative Imaging/Imaging Biomarkers and QIBA Meetings and Activities==<br />
*QI/IB Special Interest Session-<br />
Imaging Biomarkers for Clinical Care and Research<br />
Monday, November 29, 2010<br />
'''[http://www2.rsna.org/re/QI_IB_Special_Interest_Session_RSNA_2010/Index.htm Presentations]'''<br />
<br />
*SAVE-THE-DATE<br />
QIBA Annual Meeting<br />
May 24-25, 2011<br />
Renaissance Arlington Capital View, Arlington VA<br />
<br />
----<br />
<br />
NEW: '''[[How To's| "How To" help pages]]'''<br />
<br />
*[[Media:Enabling E-alerts-20100504.pdf|Enabling E-alerts]]<br />
<br />
*[[Media:Microsoft Word - WIKI PROTOCOL-v2.pdf|Posting Material]]<br />
<br />
*[[Media:Wiki Help-History Overview2.pdf|History Search]]<br />
<br />
'''''<This Wiki is a Work In Progress: read [[Help:Contents|Help]], create an [[Wiki Accounts|account]], contribute>'''''</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Main_Page&diff=2851Main Page2011-03-13T12:34:00Z<p>Abuckler: </p>
<hr />
<div>__NOTOC__<br />
This Wiki is for collaborative creation of QIBA materials and ongoing activities.<br />
<br />
='''Quantitative Imaging Biomarkers Alliance (QIBA)'''=<br />
<br />
'''QIBA Mission: Improve the value and practicality of quantitative biomarkers by reducing variability across devices, patients and time.'''<br />
<br />
<br />
QIBA is an initiative to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice by engaging researchers, healthcare professionals and industry . This involves:<br />
<br />
:* collaborating to identify needs, barriers, and solutions to develop and test consistent, reliable, valid, and achievable quantitative imaging results across imaging platforms, clinical sites, and time.<br />
:* accelerating the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.<br />
<br />
<br />
QIBA develops Profile specifications and coordinates the necessary research and qualification groundwork.<br />
:* [[What Are Profiles?]]<br />
:* [[Media:Profiling.ppt|How Does QIBA Derive Profiles?]]<br />
<br />
==QIBA Committees==<br />
QIBA currently has four active committees:<br />
:* [[Quantitative-MRI]]<br />
:**[[DCE-MRI subctte]]<br />
:**[[fMRI subctte]]<br />
:* [[Quantitative-PET]]<br />
:* [[Quantitative-CT]]<br />
:* [[COPD-Asthma]]<br />
<br />
==Documents==<br />
<br />
*[[Media:HHSN268201000050C_QIBA_Semiannual_Report_3-11-2010.doc|QIBA 1H-FY2011 Semi-annual Report(2011.03.11)]]<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_MR_specifics.pdf|"Why QIBA?" - Specifics associated with MR device and software manufacturers.]]<br />
*[[Media:HHSN268201000050C_QIBA_Proposed_Workplan_11-22-2010.doc|QIBA Work Plan (2010.11.22)]]<br />
*[[Media:EU.2009.08.04 Guideline on Clinical evaluation of diagnostic agents.pdf|EMEA Guideline on Clinical Evaluation of Diagnostic Agents (2009.08.04)]]<br />
*[[Media:EU.2009.08.04 Appendix 1 to the guideline.pdf|EMEA Guideline - Appendix 1 (2009.08.04)]]<br />
*[[Media:Oncology section.ppt|Oncology section from 2009 Imaging Biomarkers Roundtable]]<br />
*[[Media:FREEMAN_FINAL_PROOF.pdf|QIBA posters from RSNA 2008 Annual Meeting]]<br />
*[[QIBA and UPICT posters from RSNA 2009 Annual Meeting]]<br />
*[[QIBA and UPICT posters from RSNA 2010 Annual Meeting]]<br />
<br />
----<br />
<br />
==Ad Hoc Committees==<br />
<br />
:*[[Committee on Open Image Archives]]<br />
<br />
----<br />
<br />
==Quantitative Imaging/Imaging Biomarkers and QIBA Meetings and Activities==<br />
*QI/IB Special Interest Session-<br />
Imaging Biomarkers for Clinical Care and Research<br />
Monday, November 29, 2010<br />
'''[http://www2.rsna.org/re/QI_IB_Special_Interest_Session_RSNA_2010/Index.htm Presentations]'''<br />
<br />
*SAVE-THE-DATE<br />
QIBA Annual Meeting<br />
May 24-25, 2011<br />
Renaissance Arlington Capital View, Arlington VA<br />
<br />
----<br />
<br />
NEW: '''[[How To's| "How To" help pages]]'''<br />
<br />
*[[Media:Enabling E-alerts-20100504.pdf|Enabling E-alerts]]<br />
<br />
*[[Media:Microsoft Word - WIKI PROTOCOL-v2.pdf|Posting Material]]<br />
<br />
*[[Media:Wiki Help-History Overview2.pdf|History Search]]<br />
<br />
'''''<This Wiki is a Work In Progress: read [[Help:Contents|Help]], create an [[Wiki Accounts|account]], contribute>'''''</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=Main_Page&diff=2850Main Page2011-03-13T12:31:15Z<p>Abuckler: </p>
<hr />
<div>__NOTOC__<br />
This Wiki is for collaborative creation of QIBA materials and ongoing activities.<br />
<br />
='''Quantitative Imaging Biomarkers Alliance (QIBA)'''=<br />
<br />
'''QIBA Mission: Improve the value and practicality of quantitative biomarkers by reducing variability across devices, patients and time.'''<br />
<br />
<br />
QIBA is an initiative to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice by engaging researchers, healthcare professionals and industry . This involves:<br />
<br />
:* collaborating to identify needs, barriers, and solutions to develop and test consistent, reliable, valid, and achievable quantitative imaging results across imaging platforms, clinical sites, and time.<br />
:* accelerating the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.<br />
<br />
<br />
QIBA develops Profile specifications and coordinates the necessary research and qualification groundwork.<br />
:* [[What Are Profiles?]]<br />
:* [[Media:Profiling.ppt|How Does QIBA Derive Profiles?]]<br />
<br />
==QIBA Committees==<br />
QIBA currently has four active committees:<br />
:* [[Quantitative-MRI]]<br />
:**[[DCE-MRI subctte]]<br />
:**[[fMRI subctte]]<br />
:* [[Quantitative-PET]]<br />
:* [[Quantitative-CT]]<br />
:* [[COPD-Asthma]]<br />
<br />
==Working Documents==<br />
<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_MR_specifics.pdf|"Why QIBA?" - Specifics associated with MR device and software manufacturers.]]<br />
*[[Media:HHSN268201000050C_QIBA_Proposed_Workplan_11-22-2010.doc|QIBA Work Plan (2010.11.22)]]<br />
*[[Media:EU.2009.08.04 Guideline on Clinical evaluation of diagnostic agents.pdf|EMEA Guideline on Clinical Evaluation of Diagnostic Agents (2009.08.04)]]<br />
*[[Media:EU.2009.08.04 Appendix 1 to the guideline.pdf|EMEA Guideline - Appendix 1 (2009.08.04)]]<br />
*[[Media:Oncology section.ppt|Oncology section from 2009 Imaging Biomarkers Roundtable]]<br />
*[[Media:FREEMAN_FINAL_PROOF.pdf|QIBA posters from RSNA 2008 Annual Meeting]]<br />
*[[QIBA and UPICT posters from RSNA 2009 Annual Meeting]]<br />
*[[QIBA and UPICT posters from RSNA 2010 Annual Meeting]]<br />
<br />
----<br />
<br />
==Ad Hoc Committees==<br />
<br />
:*[[Committee on Open Image Archives]]<br />
<br />
----<br />
<br />
==Quantitative Imaging/Imaging Biomarkers and QIBA Meetings and Activities==<br />
*QI/IB Special Interest Session-<br />
Imaging Biomarkers for Clinical Care and Research<br />
Monday, November 29, 2010<br />
'''[http://www2.rsna.org/re/QI_IB_Special_Interest_Session_RSNA_2010/Index.htm Presentations]'''<br />
<br />
*SAVE-THE-DATE<br />
QIBA Annual Meeting<br />
May 24-25, 2011<br />
Renaissance Arlington Capital View, Arlington VA<br />
<br />
----<br />
<br />
NEW: '''[[How To's| "How To" help pages]]'''<br />
<br />
*[[Media:Enabling E-alerts-20100504.pdf|Enabling E-alerts]]<br />
<br />
*[[Media:Microsoft Word - WIKI PROTOCOL-v2.pdf|Posting Material]]<br />
<br />
*[[Media:Wiki Help-History Overview2.pdf|History Search]]<br />
<br />
'''''<This Wiki is a Work In Progress: read [[Help:Contents|Help]], create an [[Wiki Accounts|account]], contribute>'''''</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:Profile_FDG-PET_03122011.doc&diff=2849File:Profile FDG-PET 03122011.doc2011-03-13T12:30:39Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=FDG-PET_Biomarker_Ctte&diff=2848FDG-PET Biomarker Ctte2011-03-13T12:30:14Z<p>Abuckler: </p>
<hr />
<div>== Quantitative FDG-PET Technical Committee Mission ==<br />
<br />
*'''Mission; Foster adoption of ...'''<br />
**pragmatic and cost effective standards for<br />
**accurate and reproducible<br />
**longitudinal<br />
**quantitation of<br />
**biologic parameters<br />
**with clinical relevance<br />
**and known sigma<br />
<br />
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
<br />
==Meetings / Call Summaries==<br />
*[[Monthly FDG-PET Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* [[Media: Profile_FDG-PET_03122011.doc|Whole Body FDG-PET]] ''Word version of Profile applicable to multiple indications, 03-12-2011''<br />
Archive:<br />
* [[Profile: FDG-PET Whole Body]] ''First version of Profile, 2009 (currently inactive)''<br />
<br />
==Working Documents and Reference Materials==<br />
*[[Covariates Rationale]]<br />
*[[Standardized Uptake Value (SUV)]]<br />
*[[Quality Control Metrics]]<br />
*[[ROI Definition]]<br />
*[[Software Version Tracking]]<br />
<br />
*[[Media:PET-CovariatesRationale YAP 20090310.ppt|Covariates Rationale SubCtte]] ''March 2009''<br />
*[[Media:PET-DRO KINAHAN 2009-03-10.ppt|Digital Reference Objects SubCtte]] ''March 2009''<br />
*[[Media:PET-QualityControlMetrics YAP 20090224.ppt|Quality Control Metrics SubCtte]] ''March 2009''<br />
*[[Media:PET-ROI-Definitions TURKINGTON 20090306.ppt|Region of Interest SubCtte]] ''March 2009''<br />
*[[Media:PET-SoftwareVersionTracking SHAO 3-13-09-2.ppt|Software Version Tracking SubCtte]] ''March 2009''<br />
<br />
*[[Media:Boellaard-Aanbevelingen NEDPAS 2007 - EN- 17032009.pdf|NL Standardization Protocol for Quantitative FDG-PET in multi-Center Trials - Dr Ronald Boellaard]]<br />
<br />
'''The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)'''<br />
<br />
Please keep the following in mind:<br />
<br />
The development of this protocol was started about 2005 and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):<br />
<br />
*Use of oral contrast is now excluded but will be allowed in the next version<br />
*We are currently working on standards for CT as well, including GL for doing CT-QC (in cooperation with the radiologists/radiology societies in NL)<br />
*There will be an upper limit for dosage<br />
*We are working on traceable/calibrated and mutually linked sources for both PET and the dose calibrator and these will be used for absolute (rather than cross-) calibration (but in addition to the cross-calibration using FDG).<br />
*Reconstruction settings given in the protocol are indicative and are likely not applicable for future scanners and software upgrades. Therefore reconstruction parameters should be set such that they provide results that meet the specifications given for the multi-center QC experiments. Same settings should then be applied to patient studies (see also comments under "execptions/special features” and comments made in the paper by Boellaard et al. EJNMMI 2008).<br />
* Various other minor edits/typos/changes<br />
<br />
The protocol is not a step-by-step description of the logistics for doing a PET/CT study. However, it has been set up in a somewhat chronological order and may thus be used to populate (copy-paste) such a step-by-step description. Additional work required ... FDG-PET/CT Technical Committee input is highly appreciated.<br />
<br />
Submitted by Ronald Boellaard, PhD<br />
<br /><br />
*[[Media:Wahl PERCIST JNM 2009.pdf|From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors]]<br />
Submitted by Richard L. Wahl, MD and Martin A. Lodge, PhD<br />
<br />
*[[Media:05.19.2009 QIBA FDG-PET Breakout Session Notes.pdf|05.19.2009 QIBA FDG-PET/CT Breakout Session Notes]]<br />
<br />
*[[Media:QIBA FDGPET ICL.imageanalysis-Dr-Perlman-20090617.pdf|Draft FDG-PET ICL Logistics Outline]]<br />
Submitted by Eric S. Perlman, MD<br />
<br />
*[[Media:SUV for PET Paper.pdf|Reevaluation of the Standardized Uptake Value for FDG: Variations with Body Weight and Methods for Correction - ''Radiology'' 1999; 213: 521-525]]<br />
<br />
==Slide Presentations==<br />
*[[QIBA Informational Meeting (Dec 1st at RSNA 2008) - Slide Content Review]]<br />
*[[Media:Dr Frank Breakout + PETCT Tech Cmte 081204.ppt|QIBA Working Meeting (Dec 4th at RSNA 2008) - FDG-PET/CT Breakout Session Slide Deck]]<br />
*[[Fused Images]]<br />
*[[Media:FDG-PET11-29.ppt]]<br />
*[[Media:Mission FDG PETCT Tech Cmte 080520-DR-FRANK-20090310.ppt|QIBA FDG-PET/CT Mission Statement - 2009.03.10]]<br />
*[[Media:ProfilingSlides-ABuckler-20090331.pdf|QIBA Profiling Process-03.31.2009 (Andrew Buckler, MS)]]<br />
*[[Media:Frank-FDG-PET-20090520.ppt|FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank]]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.03.12_UPICT_CT_small_nodule_V0_6.doc&diff=2847File:2011.03.12 UPICT CT small nodule V0 6.doc2011-03-13T12:28:54Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.03.12_Profile_CT_small_nodule_V0_6.doc&diff=2846File:2011.03.12 Profile CT small nodule V0 6.doc2011-03-13T12:28:39Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc&diff=2845File:2010.09.09 UPICT V1 4 1 FIELD TEST.doc2011-03-13T12:27:27Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2844CT Volumetry Biomarker Ctte2011-03-13T03:02:05Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.02.28.Profile_CT_advanced_disease_V1_6.doc|VIA Profile v1.6]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.02.28.Protocol_CT_advanced_disease_V1_6.doc|VIA Protocol v1.6]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.03.12_Profile_CT_small_nodule_V0_6.doc|Small Nodule Profile v0.6]] ''Word version of Profile applicable to small pulmonary nodules''<br />
** [[Media: 2011.03.12_UPICT_CT_small_nodule_V0_6.doc|Small Nodule Protocol v0.6]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2843CT Volumetry Biomarker Ctte2011-03-13T01:54:50Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.02.28.Profile_CT_advanced_disease_V1_6.doc|VIA Profile v1.6]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.02.28.Protocol_CT_advanced_disease_V1_6.doc|VIA Protocol v1.6]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.02.27.Profile_CT_small_nodule_V0_5.doc|Small Nodule Profile v0.5]] ''Word version of Profile applicable to small pulmonary nodules''<br />
** [[Media: 2011.02.27.Protocol_CT_small_nodule_V0_5.doc|Small Nodule Protocol v0.5]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2842CT Volumetry Biomarker Ctte2011-03-13T01:53:51Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.02.28.Profile_CT_advanced_disease_V1_6.doc|VIA Profile v1.6]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.02.28.Protocol_CT_advanced_disease_V1_6.doc|VIA Protocol v1.6]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.02.27.Profile_CT_small_nodule_V0_5.doc|Small Nodule Profile v0.5]] ''Word version of Profile applicable to small pulmonary nodules''<br />
** [[Media: 2011.02.27.Protocol_CT_small_nodule_V0_5.doc|Small Nodule Protocol v0.5]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: B.2010.09.09_UPICT_V1_4_1_FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2841CT Volumetry Biomarker Ctte2011-03-13T01:51:03Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.02.28.Profile_CT_advanced_disease_V1_6.doc|VIA Profile v1.6]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.02.28.Protocol_CT_advanced_disease_V1_6.doc|VIA Protocol v1.6]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.02.27.Profile_CT_small_nodule_V0_5.doc|Small Nodule Profile v0.5]] ''Word version of Profile applicable to small pulmonary nodules''<br />
** [[Media: 2011.02.27.Protocol_CT_small_nodule_V0_5.doc|Small Nodule Protocol v0.5]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: B.2010.09.09_UPICT_CT_Lung_Mass_V1_4_1 FIELD_TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2836CT Volumetry Biomarker Ctte2011-03-06T00:56:13Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.02.28.Profile_CT_advanced_disease_V1_6.doc|VIA Profile v1.6]] ''Word version as preparatory for drafting "version two" applicable to late stage disease in multiple organ systems''<br />
** [[Media: 2011.02.28.Protocol_CT_advanced_disease_V1_6.doc|VIA Protocol v1.6]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.02.27.Profile_CT_small_nodule_V0_5.doc|Small Nodule Profile v0.5]] ''Word version of Profile applicable to small pulmonary nodules''<br />
** [[Media: 2011.02.27.Protocol_CT_small_nodule_V0_5.doc|Small Nodule Protocol v0.5]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4_1 FIELD TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.02.28.Profile_CT_advanced_disease_V1_6.doc&diff=2835File:2011.02.28.Profile CT advanced disease V1 6.doc2011-03-06T00:55:28Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.02.28.Protocol_CT_advanced_disease_V1_6.doc&diff=2834File:2011.02.28.Protocol CT advanced disease V1 6.doc2011-03-06T00:55:15Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.02.27.Profile_CT_small_nodule_V0_5.doc&diff=2833File:2011.02.27.Profile CT small nodule V0 5.doc2011-03-06T00:54:32Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:2011.02.27.Protocol_CT_small_nodule_V0_5.doc&diff=2832File:2011.02.27.Protocol CT small nodule V0 5.doc2011-03-06T00:54:11Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2831CT Volumetry Biomarker Ctte2011-03-06T00:53:23Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.02.28.Profile_CT_advanced_disease_V1_6.doc|VIA Profile v1.6]] ''Word version as preparatory for drafting "version two" applicable to late stage disease''<br />
** [[Media: 2011.02.28.Protocol_CT_advanced_disease_V1_6.doc|VIA Protocol v1.6]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.02.27.Profile_CT_small_nodule_V0_5.doc|Small Nodule Profile v0.5]] ''Word version of Profile applicable to multiple indications''<br />
** [[Media: 2011.02.27.Protocol_CT_small_nodule_V0_5.doc|Small Nodule Protocol v0.5]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4_1 FIELD TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=CT_Volumetry_Biomarker_Ctte&diff=2830CT Volumetry Biomarker Ctte2011-03-06T00:53:01Z<p>Abuckler: </p>
<hr />
<div>==Project Snapshot==<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media: Plan as of 11-8-10.jpg|Project plan]] ''.jpg version as of 11-8-10''<br />
'''[[:Category:Datasets| See the Datasets page]]''' of the [[Catalog|QIBA Resource Catalog]]<br />
<br />
==Meetings / Call Summaries==<br />
<br />
*[[Call Agenda Topics]]<br />
*[[Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* Advanced disease:<br />
** [[Media: 2011.02.28.Profile_CT_advanced_disease_V1_6.doc|VIA Profile v1.6]] ''Word version as preparatory for drafting "version two" applicable to late stage disease''<br />
** [[Media: 2011.02.28.Protocol_CT_advanced_disease_V1_6.doc|VIA Profile v1.6]] ''UPICT Protocol''<br />
* Small nodule:<br />
** [[Media: 2011.02.27.Profile_CT_small_nodule_V0_5.doc|Small Nodule Profile v0.5]] ''Word version of Profile applicable to multiple indications''<br />
** [[Media: 2011.02.27.Protocol_CT_small_nodule_V0_5.doc|Small Nodule Protocol v0.5]] ''UPICT Protocol''<br />
<br />
Field Test:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4_1 FIELD TEST.doc|VIA Protocol v1.4.1]] ''Word version currently under field test as "version one" applicable to late stage disease, 09-11-2010''<br />
==Working Documents==<br />
Active:<br />
* [[VolCT - Group 1B]] - Focus on Volume Change Analysis of Pulmonary Nodules in Diagnostic Settings <br />
* [[VolCT - Group 1C]] - Model Sources of Variability from a Systems Engineering Analysis<br />
* [[VolCT - Group 3A]] - Characterize variability due to algorithm using phantoms<br />
* [[VolCT - Group 3B]] - Characterize clinical utility/efficacy with respect to clinical endpoints<br />
<br />
No longer active:<br />
*[[Media: 2010.09.09.UPICT_CT_Lung_Nodule_V1_4a.cleaner copy.doc|VIA Protocol v1.4]] ''Word version known as field test v1.0, 09-09-2010''<br />
* [http://docs.google.com/Doc?docid=0ASSwlnzdbPEGZHJyc2pxcF8zcHFkdnhqY3A&hl=en| UPICT Template for CT Lung Nodule Protocol] ''Google doc version of v1.4 WIP''<br />
*[[Media:Quantification in Imaging-Dr Dirk Colditz-20100823.ppt|Quantification in Imaging-Dr Dirk Colditz]] ''August 23, 2010''<br />
*[[Media:Work breakdown for volCT-formatted.doc| Work Breakdown for Volumetric CT]] ''07.12.10''<br />
* [[VolCT - Group 1A]] - Analyze Bias/Variance where Ground Truth is Known Deterministically<br />
*[[Media:2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors.long version.doc|2009 12 31 Review of Volumetric Image Analysis in Patients with Solid Tumors - long version]]<br />
*[[Media: QIBA_Vol-CT_Profile_v1.1-ABuckler-20090903.doc|VIA Profile v1.1]] ''Word version 09-03-2009''<br />
* [[Profile: CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites]] ''Last updated 6/2009''<br />
* [[Profile: CT Lung Nodule - Small Nodule in Neoadjuvant Setting]] ''Last updated 6/2009''<br />
*[[Media:2008.09.15.Validation_Roadmap_VOL-CT_Image_Analysis.pdf|Validation Roadmap - P. David Mozley, MD]]<br />
*[[Media:Mr ODonnell QIBA Process Roadmap 20090629.ppt.pdf|Thoughts on the QIBA Process: Profiles, UPICT & Measurements by Kevin O’Donnell-20090629]]<br />
* [[VolCT - Group 2]] - Set Standards for using Volumetric Imaging in Clinical Trials<br />
* [[Profile Strategy for Vol CT]]<br />
* [[Initial Target Selection]] - describing the early prioritization discussions and settling on Lung Tumor Volumes<br />
*[[Media:2008.12.16.Sources_of_Variability_-_Andrew_Buckler.xls|Sources of Variability - Andrew Buckler]]<br />
<br />
==Reference Materials==<br />
<br />
*Dr Petrick's 2011 SPIE Presentation Materials<br />
*[[Media:Spie2011 NP QIBA1A-Talk-v05-final-1.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Talk]]<br />
*[[Media:Spie2011 NP QIBA1A-Paper-v08-final-2.pdf|“Evaluation of 1D, 2D and 3D nodule size estimation by radiologists for spherical and non-spherical nodules through CT thoracic phantom imaging” - Paper]]<br />
<br />
<br />
*Are we ready? A time for measurement of physiological parameters of the lung using multidetector row CT scans. Hatabu H. Acad Radiol. 2009 Mar; 16(3):249. [http://www.academicradiology.org/issues/contents?issue_key=S1076-6332(09)X0002-4 Academic Radiology]<br />
<br />
* [http://radiology.rsnajnls.org/cgi/content/full/243/2/527#T2 Radiology 2007 - Coronary Calcium Scoring] - This paper by Dr. McCollough et al is may be seen to be analaogous to our work in that it addresses similar issues (e.g. achieving "standard" noise levels). It could be thought of as an early draft of a Calcium Scoring profile, including both groundwork and equipment specifications.<br />
*Helical multidetector row quantitative computed tomography (QCT) precision. Bligh M, Bidaut L, White RA, Murphy WA Jr, Stevens DM, Cody DD. Acad Radiol. 2009 Feb; 16(2):150-9. [http://www.academicradiology.org/article/S1076-6332(08)00499-6/abstract Academic Radiology]<br />
*Comparison of the accuracy of CT volume calculated by circumscription to prolate ellipsoid volume (bidimensional measurement multiplied by coronal long axis). Rkein AM, Harrigal C, Friedman AC, Persky D, Krupinski E. Acad Radiol. 2009 Feb; 16(2):181-6. [http://www.academicradiology.org/article/S1076-6332(08)00530-8/abstract Academic Radiology]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:Profile_FDG-PET_03052011.doc&diff=2829File:Profile FDG-PET 03052011.doc2011-03-06T00:48:39Z<p>Abuckler: </p>
<hr />
<div></div>Abucklerhttps://qibawiki.rsna.org/index.php?title=FDG-PET_Biomarker_Ctte&diff=2828FDG-PET Biomarker Ctte2011-03-06T00:48:11Z<p>Abuckler: </p>
<hr />
<div>== Quantitative FDG-PET Technical Committee Mission ==<br />
<br />
*'''Mission; Foster adoption of ...'''<br />
**pragmatic and cost effective standards for<br />
**accurate and reproducible<br />
**longitudinal<br />
**quantitation of<br />
**biologic parameters<br />
**with clinical relevance<br />
**and known sigma<br />
<br />
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
<br />
==Meetings / Call Summaries==<br />
*[[Monthly FDG-PET Call Summaries]]<br />
<br />
==Profile Development==<br />
Drafting:<br />
* [[Media: Profile_FDG-PET_03052011.doc|Whole Body FDG-PET]] ''Word version of Profile applicable to multiple indications, 03-05-2011''<br />
Archive:<br />
* [[Profile: FDG-PET Whole Body]] ''First version of Profile, 2009 (currently inactive)''<br />
<br />
==Working Documents and Reference Materials==<br />
*[[Covariates Rationale]]<br />
*[[Standardized Uptake Value (SUV)]]<br />
*[[Quality Control Metrics]]<br />
*[[ROI Definition]]<br />
*[[Software Version Tracking]]<br />
<br />
*[[Media:PET-CovariatesRationale YAP 20090310.ppt|Covariates Rationale SubCtte]] ''March 2009''<br />
*[[Media:PET-DRO KINAHAN 2009-03-10.ppt|Digital Reference Objects SubCtte]] ''March 2009''<br />
*[[Media:PET-QualityControlMetrics YAP 20090224.ppt|Quality Control Metrics SubCtte]] ''March 2009''<br />
*[[Media:PET-ROI-Definitions TURKINGTON 20090306.ppt|Region of Interest SubCtte]] ''March 2009''<br />
*[[Media:PET-SoftwareVersionTracking SHAO 3-13-09-2.ppt|Software Version Tracking SubCtte]] ''March 2009''<br />
<br />
*[[Media:Boellaard-Aanbevelingen NEDPAS 2007 - EN- 17032009.pdf|NL Standardization Protocol for Quantitative FDG-PET in multi-Center Trials - Dr Ronald Boellaard]]<br />
<br />
'''The Netherlands Standardization Protocol for Quantitative FDG-PET in Multi-center Trials (English translation of Version 1)'''<br />
<br />
Please keep the following in mind:<br />
<br />
The development of this protocol was started about 2005 and approved more than 1 year ago in The Netherlands (NL). However, with gained insight, changes are scheduled to be incorporated in the next version by 2010. The following changes will be made (consider them being applied already or underway):<br />
<br />
*Use of oral contrast is now excluded but will be allowed in the next version<br />
*We are currently working on standards for CT as well, including GL for doing CT-QC (in cooperation with the radiologists/radiology societies in NL)<br />
*There will be an upper limit for dosage<br />
*We are working on traceable/calibrated and mutually linked sources for both PET and the dose calibrator and these will be used for absolute (rather than cross-) calibration (but in addition to the cross-calibration using FDG).<br />
*Reconstruction settings given in the protocol are indicative and are likely not applicable for future scanners and software upgrades. Therefore reconstruction parameters should be set such that they provide results that meet the specifications given for the multi-center QC experiments. Same settings should then be applied to patient studies (see also comments under "execptions/special features” and comments made in the paper by Boellaard et al. EJNMMI 2008).<br />
* Various other minor edits/typos/changes<br />
<br />
The protocol is not a step-by-step description of the logistics for doing a PET/CT study. However, it has been set up in a somewhat chronological order and may thus be used to populate (copy-paste) such a step-by-step description. Additional work required ... FDG-PET/CT Technical Committee input is highly appreciated.<br />
<br />
Submitted by Ronald Boellaard, PhD<br />
<br /><br />
*[[Media:Wahl PERCIST JNM 2009.pdf|From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors]]<br />
Submitted by Richard L. Wahl, MD and Martin A. Lodge, PhD<br />
<br />
*[[Media:05.19.2009 QIBA FDG-PET Breakout Session Notes.pdf|05.19.2009 QIBA FDG-PET/CT Breakout Session Notes]]<br />
<br />
*[[Media:QIBA FDGPET ICL.imageanalysis-Dr-Perlman-20090617.pdf|Draft FDG-PET ICL Logistics Outline]]<br />
Submitted by Eric S. Perlman, MD<br />
<br />
*[[Media:SUV for PET Paper.pdf|Reevaluation of the Standardized Uptake Value for FDG: Variations with Body Weight and Methods for Correction - ''Radiology'' 1999; 213: 521-525]]<br />
<br />
==Slide Presentations==<br />
*[[QIBA Informational Meeting (Dec 1st at RSNA 2008) - Slide Content Review]]<br />
*[[Media:Dr Frank Breakout + PETCT Tech Cmte 081204.ppt|QIBA Working Meeting (Dec 4th at RSNA 2008) - FDG-PET/CT Breakout Session Slide Deck]]<br />
*[[Fused Images]]<br />
*[[Media:FDG-PET11-29.ppt]]<br />
*[[Media:Mission FDG PETCT Tech Cmte 080520-DR-FRANK-20090310.ppt|QIBA FDG-PET/CT Mission Statement - 2009.03.10]]<br />
*[[Media:ProfilingSlides-ABuckler-20090331.pdf|QIBA Profiling Process-03.31.2009 (Andrew Buckler, MS)]]<br />
*[[Media:Frank-FDG-PET-20090520.ppt|FDG-PET/CT Technical Committee summary 2009.05.20 Richard Frank]]</div>Abucklerhttps://qibawiki.rsna.org/index.php?title=File:Profile_V0_1_Asthma_COPD.doc&diff=2827File:Profile V0 1 Asthma COPD.doc2011-03-06T00:46:35Z<p>Abuckler: </p>
<hr />
<div></div>Abuckler